Kertzi
Nov 20, 1:25 PM
$MTVA The Dong-A (Korea) risk nobody seems to be discussing.
MetaVia reportedly owes Dong-A ST approximately
$2.1 million, including overdue invoices and accrued clinical costs. Dong-A is not just a major shareholder — it is also a key supplier, the original developer and the licensor of both drug candidates.
What happens if Dong-A decides it has had enough?
It could demand payment and, if contractual conditions are met, suspend services or terminate agreements. Losing Dong-A's support could seriously disrupt the development of both assets.
With cash running low, Nasdaq's minimum equity requirement already breached, and no clear financing solution in sight, this is a serious risk shareholders should not ignore.
Could Dong-A be MetaVia's biggest lifeline — or ultimately the reason this company runs out of road?
0 replies